… for quinolone-3-diarylethers to induce resistance in malaria … Quinolone-3-diarylethers
represent a new antimalarial series … of atovaquone, a clinical drug with the same enzyme target. …

… Ideally antimalarial drugs can be developed which target … Here we introduce 4-(1H)-quinolone-3-diarylethers
that are … stable, and is highly active in rodent malaria models. Given a low …

… The in vivo antimalarial efficacy of this initial series of ELQ derivatives is summarized in …
lead, as well as chloroquine, a 4-aminoquinoline antimalarial drug. Consistent with earlier …

… of new anti-malarial drugs to curb the disease. The quinolones are a promising class of
compounds, with some demonstrating potent in vitro activity against the malaria parasite. This …

… of new antimalarial drugs was neglected especially due to the fact that it is common in low- …
These quinolone-3diarylethers represent a new class of antimalarials highly active against P…

… , was initially investigated as an antimalarial drug against avian malaria affecting canaries, …
avian malaria model gave hope to the discovery of an entirely novel class of antimalarial …

… The goal for developing new antimalarial drugs is to find a … The 4(1H)-quinolone-3-diarylethers
are selective potent … These compounds are highly active against the human malaria …

… a pressing need for new drugs to address … antimalarial drug resistance landscape and to
make advances on the goal of worldwide eradication of the disease, the Medicines for Malaria …

… Atovaquone, a cytochrome bc 1 Q o site inhibitor, is combined with proguanil for the
prophylaxis and treatment of malaria (5). Atovaquone is a first-line treatment in combination with …

… Antimalarial drugs will continue to be an important part of this effort. This may occur through
the discovery of new … will be a useful expansion to the arsenal of antimalarial drugs. …